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*HI = (D2%-D98%)/D50% $p: threshold for statistical significance p< 0.05 
 
Conclusions: Our results indicate that both techniques are able to 
produce plans with a good coverage of PTVs and an acceptable sparing 
of the contralateral parotid gland for OPC, despite a slight advantage 
of RA for dosimetric analysis of PTV. In addition,the NTID was 
significantly lower with RA. However, the clinical benefit ofthese 
dosimetric advantages needs further investigation. 
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Purpose/Objective: The significance of breath hold for reducing heart 
and lung dose for RT of left sided breast cancer, especially when 
internal mammary (IM) nodes are included, has been established by 
many investigators. In contrary, the role of volumetric modulated arc 
therapy (VMAT) is still debated: although the dose to the ipsilateral 
lung and heart may be decreased compared to conformal RT, the dose 
delivered to the contralateral breast and lung may be increased. In 
our study, we investigate the dose distribution of VMAT (RapidArc®) in 
combination with voluntary moderately deep inspiration breath hold 
(vmDIBH) for left-sided breast cancer patients treated to breast/chest 
wall and IM and periclavicular nodes. 
Materials and Methods: A planning study of free breathing (FB) and 
vmDIBH in combination with conformal or RapidArc® plans is 
conducted on 10 patients, giving 4 possible combinations per patient. 
The following dosimetric parameters were compared: homogeneity 
index (HI) for PTV, doses to heart, lung, and contralateral breast. 
Results: RapidArc® plans had a better HI: 0.82 for FB and 0.81 for 
vmDIBH vs. 0.73 (FB) and 0.75 (vmDIBH)] for 3D-CRT. The average 
doses to the total lung, heart and contralateral breast are displayed in 
the table for the first 3 patients.  
 
  3D-CRT RapidArc 
  FB vmDIBH FB vmDIBH 
Heart V20 (%) 8.7 2.4 2.1 0.7 
 V5 (%) 40.5 28.6 12.2 10.3 
 Mean (Gy) 6.9 4.1 3.6 3.0 
Lung V20 (%) 16.9 14.4 7.2 6.8 
 V5 (%) 36.4 32.0 34.9 32.7 
 Mean (Gy) 8.1 7.1 6.1 5.6 
CL breast V20 (%) 0.3 0.5 0.0 0.0 
 V5(%) 0.8 1.2 5.0 2.7 
 Mean (Gy) 0.4 0.5 2.1 1.3 
 
Conclusions: RapidArc® plans are superior compared to 3D-CRT for 
dose homogeneity to the PTV, heart dose and V20 and mean dose of 
the lung. This goes at the expense of a slightly increased dose to the 
contralateral breast. We confirm a decrease in heart dose using 
vmDIBH combined with 3D-CRT. Since the addition of vmDIBH to 
RapidArc® leads to a slight further improvement in heart dose, as well 
as a reduction of the dose to the contralateral breast, we conclude 
that the combination of RapidArc® and vmDIBH is a promising 
technique for locoregional RT for left sided breast cancer patients.  
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Purpose/Objective: The major challenge for MRI-based RTP is the 
lack of electron density information in the images. This research 
aimed to convert the T1/T2*-weighted MRI intensity values into 
electron density values in pelvis, and to enable accurate MRI-based 
RTP for prostate cancer patients. 
Materials and Methods: Seventeen randomly chosen patients were set 
either into a data collection group (10 patients) or into a test group so 
that both of the groups included variety of different size patients. The 
standard CT image HUs and the MRI intensity values were analyzed for 
pelvic soft tissues of each data collection patient. By using the 
collected data a threshold based segmentation method was 
constructed to convert the soft tissues such as fat, muscle and urine, 
from MRI intensity values into HUs. For the bones our previously 
published1, 2 conversion model was utilized with minor 
adjustments.The soft tissue HUs in the created pseudo-CT image of 
each test group patient were compared to the HUs in the standard CT 
image. Moreover, the dose distributions in the pseudo-CT images were 
compared to those in the CT images by using a 7-field IMRT plan. 
Results: Figure 1 shows an example of the constructed pseudo-CT 
images. The comparison between results in the pseudo-CT images and 
in the standard CT images with pilot 7 test patients illustrated that 
the average deviations in each pelvic soft tissue were between 7 and 
15 HUs. Furthermore, 91% of the investigated ROIs in the images were 
within 20 HUs, and 99% within 50 HUs. The average target doses (PTV 
volumes 5%, 50%, 95% and mean) in the pseudo-CT images were within 
0.7% compared to those in the CT images. Over 1% dose deviations 
were detected with two patients. The improvements for dose 
calculation accuracy when using the soft tissue conversion instead of 
setting all soft tissues as water equivalent, but having bones 
converted with the same technique, were up to over 1 percentage 
unit (with obese patients). 
 
 Figure 1: A constructed MRI-based pseudo-CT image of a prostate 
cancer patient. 
 
Conclusions: This study indicates that it is possible to construct 
pseudo-CT images by converting the MRI intensity values into electron 
density values in pelvis, and to use these images for accurate MRI-
based prostate RTP. The examinations illustrated that by including the 
heterogeneous soft tissues into the pseudo-CT images the dose 
calculation accuracy can be improved especially with obese patients.  
1 Kapanen and Tenhunen, 'T1/T2*-weighted MRI provides clinically 
relevant pseudo-CT density data from pelvic bones in MRI-only based 
radiotherapy treatment planning.' Acta Onc., Early Online: 1-7, 
DOI:10.3109/0284186X.2012.692883, 2012. 
2 Korhonen et al, 'Absorbed doses behind bones with MR image-based 
dose calculations for radiotherapy treatment planning.' Med.Phys. 40 
(1), 2013. 
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Purpose/Objective: To compare two models of multileaf collimators 
(MLCs) with different leaf width for the treatment of intracranial 
lesions using intensity modulated radiosurgery (IMRS) technique. 
Materials and Methods: Eclipse TPS (version 10.0) was used to 
compute IMRS plans for 20 cases of small brain lesions (range: 0.5 to 
18.3 cc). Two differents models of MLC (Varian) were configured in 
Eclipse for a Varian Clinac 2100 CD: one with standard 5 mm leaf 
width ('STD') and the other with 2.5 mm leaf width ('HD'). For each 
patient, two IMRS plans were created using the same beam 
arrangement, same constraints during the optimization process,same 
number of optimization cycles, same dose calculation algorithm (AAA, 
1 mm calculation grid size),and same dose prescription (99% of the 
target volume receiving the 100% prescriptiond ose); but each plan 
had a different MLC device, resulting a 'standardplan' and a 'HD plan' 
for each patient. Resulting plans for each patient were compared in 
terms of: 1) conformity index (CI; RTOG definition); 2) dose gradient 
(G; defined as the difference between the equivalent sphere radius of 
the prescription and half-prescription isodoses); 3) volume of normal 
brain receiving 12 Gy or more (V12) and 4) normal tissue volume (NTD) 
receiving the 50%, 70% and 90% of prescription dose (NTD50, NTD70 
